Hepatitis Delta Treatment: Where We Are and Where We Are Headed - podcast episode cover

Hepatitis Delta Treatment: Where We Are and Where We Are Headed

Mar 03, 202217 minEp. 139
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

Treatment options for hepatitis delta virus (HDV) are lacking, but many exciting agents are under investigation. Hear Drs Nancy Reau and Stefan Zeuzem discuss their thoughts on up-and-coming agents for treating HDV, and explore what questions need answering to most effectively use currently available and emerging therapies, which include:

  • Bulevirtide
  • Interferon λ
  • Lonafarnib

Presenters:

Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine I
JW Goethe University Hospital
Frankfurt, Germany

Link to full program:
https://bit.ly/3tlxa0H


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

For the best experience, listen in Metacast app for iOS or Android